Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine, Inc. (PRME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates -- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PRME
Bullish
high confidence
Mentioned
$PRME
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PRMEBullishMed
01

Why it matters

The combination of clinical progress and a sizable capital raise provides fresh material for investors, potentially prompting short‑term buying.

02

Market read

First‑time disclosure of trial dosing and IND clearance, plus a $143.7M financing, makes this a material biotech news event.

03

What to watch

The $143.7M raise may dilute existing shareholders; cash runway through 2027 still leaves funding gaps for later-stage trials.

Relevance 8/10Novelty 8/10Timing: post filing today
AlphAI · Earnings readPRME · Q3 2026 · ended 2026-09-30

Prime Medicine reports Q3 2026 net loss of $39.0 million versus $50.6 million a year earlier, dosing of first Wilson disease patient, and $143.7 million gross public offering

→Mixed quarter

Net loss and operating expenses fell year over year and the company closed a $143.7 million gross offering, but revenue was $4,213 thousand, reported cash and investments fell to $61,157 thousand (balance sheet) or $74.8 million (cash, equivalents, investments and restricted cash), and total stockholders' equity dropped to $8,437 thousand. The filing gives no numeric guidance.

Revenue
$4.21M
EPS · GAAP
$(0.22)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$4.21M––
Collaboration revenue, related party, three months ended September 30, 2026GAAP$4.21M––
Collaboration revenue, other, three months ended September 30, 2026GAAP—––
Research and development expenses, three months ended September 30, 2026GAAP$34.1M––
General and administrative expenses, three months ended September 30, 2026GAAP$10M––
Total operating expenses, three months ended September 30, 2026GAAP$44.14M––
Loss from operations, three months ended September 30, 2026GAAP−$39.93M––
Interest income, three months ended September 30, 2026GAAP$555K––
Accretion (amortization) of investments, three months ended September 30, 2026GAAP$274K––
Change in fair value of short-term investment, related party, three months ended September 30, 2026GAAP—––
Other income, net, three months ended September 30, 2026GAAP$54K––
Total other income, net, three months ended September 30, 2026GAAP$883K––
Net loss attributable to common stockholders, three months ended September 30, 2026GAAP$39M––
Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP$(0.22)––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • Underwritten public offering closed in November 2026, including full exercise of the underwriters' option to purchase additional shares: $143.7 million gross proceeds before underwriting discounts and offering expenses; net proceeds approximately $134.7 million after underwriting discounts, commissions and offering expenses.
  • Pro-forma cash, cash equivalents, investments and restricted cash of approximately $209.5 million, as stated in the business update.

What drove it

  • The company states that R&D expenses were lower than in Q3 2025 because R&D expense in Q3 2025 was higher due to the issuance of restricted stock units in that quarter.
  • The company states that facility cost related to lab equipment repair and maintenance decreased during Q3 2026, also lowering R&D expenses.
  • The company states that the decrease in G&A expenses was primarily driven by lower corporate legal fees.
  • The company states that PM647 IND clearance followed the July 2026 binding resolution of its arbitration with Beam Therapeutics, in which the Tribunal declared PM647 within Prime Medicine's Field.
  • Revenue rose to $4,213 thousand from $1,225 thousand, consisting entirely of collaboration revenue from a related party in Q3 2026; the filing does not explain the increase.

Concerns

  • Reported cash and investments fell from $177,680 thousand at December 31, 2025 to $61,157 thousand at September 30, 2026, before the November 2026 offering.
  • Total stockholders' equity fell from $120,868 thousand to $8,437 thousand, while total liabilities were $205,418 thousand at September 30, 2026.
  • The company's liquidity statement runs only through 2027, with no figure for cash need beyond that date.
  • Revenue of $4,213 thousand is small relative to operating expenses of $44,139 thousand, and the loss from operations was $(39,926) thousand.
  • Net loss per share of $(0.22) is calculated on weighted-average shares that rose to 177,857,047 from 160,503,183 in the prior-year quarter (share counts as printed).

What to watch

  • Initial clinical data from the PM577a Phase 1/2 trial in Wilson disease, expected in 2027.
  • Initial clinical data from the PM647 Phase 1/2 trial in AATD, expected in 2027, after the trial is initiated.
  • Planned BLA submission for PM359 in the first half of 2027.
  • Continued enrollment in the PM577a trial and initiation of the PM647 trial.
  • Cash runway guidance through 2027 and any update on funding needs beyond that date.
  • Effect, if any, of the FDA draft guidance on individualized genome editing, which the company says could create an opportunity if finalized.

Balance sheet and cash flow

  • Cash, cash equivalents, and investments (balance sheet, unaudited): $61,157 thousand as of September 30, 2026 versus $177,680 thousand as of December 31, 2025.
  • Cash, cash equivalents, investments and restricted cash: $74.8 million as of September 30, 2026 versus $191.4 million as of December 31, 2025, as stated in the financial results section.
  • Total assets: $213,855 thousand as of September 30, 2026 versus $342,733 thousand as of December 31, 2025.
  • Total liabilities: $205,418 thousand as of September 30, 2026 versus $221,865 thousand as of December 31, 2025.
  • Total stockholders' equity: $8,437 thousand as of September 30, 2026 versus $120,868 thousand as of December 31, 2025.
  • Company guidance on liquidity: cash, cash equivalents and investments as of September 30, 2026, together with net proceeds of $134.7 million from the November 2026 offering, are expected to be sufficient to fund operating expenses and capital expenditure requirements through 2027.
  • No cash flow statement (operating or free cash flow) is included in the filing.

Analysis

Prime Medicine reported a Q3 2026 GAAP net loss of $39.0 million, compared with $50.6 million in Q3 2025. The reduction came from total operating expenses of $44,139 thousand versus $55,198 thousand, with R&D at $34.1 million (versus $44.0 million) and G&A at $10.0 million (versus $11.2 million). The company attributes the R&D decline partly to restricted stock unit issuance in Q3 2025 and lower lab equipment repair and maintenance costs, and the G&A decline to lower corporate legal fees. Total revenue was $4,213 thousand, all of it collaboration revenue from a related party, up from $1,225 thousand. The filing does not provide a prior-quarter comparison or a percentage change for revenue.

Below the operating line, total other income, net was $883 thousand, down from $3,391 thousand. The prior-year quarter included a $1,454 thousand change in fair value of a related-party short-term investment that did not recur, and interest income fell to $555 thousand from $1,141 thousand. Net loss per share was $(0.22), against $(0.32) a year earlier. The filing gives weighted-average shares of 177,857,047 this quarter versus 160,503,183, so the per-share improvement is smaller than the dollar improvement in net loss.

The balance sheet shows the funding pressure behind the period. Cash, cash equivalents, investments and restricted cash was $74.8 million at September 30, 2026, against $191.4 million at December 31, 2025, and balance sheet cash and investments were $61,157 thousand against $177,680 thousand. Total stockholders' equity fell to $8,437 thousand from $120,868 thousand. The November 2026 underwritten offering, with the underwriters' option fully exercised, raised $143.7 million gross and about $134.7 million net, lifting pro-forma cash to approximately $209.5 million. Management states that this combined position funds operations and capital expenditures through 2027. The filing gives no cash flow statement and no share count after the offering.

On the pipeline, the company reported first patient dosing in the Phase 1/2 PM577a Wilson disease trial, FDA IND clearance for PM647 in AATD, and a planned BLA submission for PM359 in the first half of 2027, with initial clinical data for PM577a and PM647 expected in 2027. These are business milestones stated by the company, and the filing contains no clinical results or regulatory outcomes beyond the IND clearance and designations listed. The filing contains no numerical guidance for revenue, expenses or margins. The only forward figure is the runway statement, so there is no prior outlook to compare against.

Management, verbatim

Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy,

Allan Reine, M.D., Chief Executive Officer, Prime Medicine

Looking ahead, we expect 2027 to be a meaningful year for the patient communities we hope to treat, with initial clinical data anticipated from both PM577a and PM647 and a planned BLA submission for PM359.

Allan Reine, M.D., Chief Executive Officer, Prime Medicine

Not in the filing

stated, not guessed
  • No prior-year or prior-quarter percentage changes are printed for any metric, so all yoy_change and qoq_change fields are null.
  • Prior-quarter (Q2 2026) figures are not provided in the filing.
  • Total revenue and related-party collaboration revenue have no printed percentage change.
  • No cash flow statement; operating cash flow, investing cash flow and free cash flow are not reported.
  • No numerical financial guidance for revenue, operating expenses, gross margin or tax rate; the only forward statement is cash sufficiency through 2027.
  • No previous outlook provided, so vs_prior_guidance is empty.
  • No segment or geographic revenue breakdown beyond total and related-party collaboration revenue.
  • No gross margin, cost of sales or tax lines printed.
  • Cash, cash equivalents, investments and restricted cash at December 31, 2025 is printed for a different date than a year-over-year comparison, so prior_year is null on that row and the figure appears in balance_sheet_cash_flow instead.
  • Post-offering share count and per-share figures after the November 2026 offering are not reported.
  • Explanation for the revenue increase is not given in the filing.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Prime Medicine, a Nasdaq‑listed gene‑editing company, filed its quarterly 8‑K reporting financials and key R&D updates.

Company-level read

Ticker impact

$PRMEBullishHigh confidence
Context

SEC 8‑K filing discloses Q3 2026 results, $143.7M capital raise, first patient dosing in Wilson disease trial and FDA IND clearance for PM647.

Expected impact

likely upward pressure as investors price in trial progress and increased cash balance

Evidence & confidence

The filing provides first‑time disclosure of dosing and IND clearance, plus a sizable equity raise, which are material catalysts for a biotech at this stage.

Market effects

Strengthens outlook for the gene‑editing biotech sector as Prime Medicine demonstrates in‑vivo progress.

Adds to US biotech momentum; may lift related Nasdaq biotech peers.

Highlights FDA's openness to prime editing therapies, relevant for global gene‑editing developers.

Counterpoint

If trial data disappoints or regulatory hurdles arise, the recent financing could be seen as dilution risk.

Key entities

  • Prime Medicine, Inc.

    Biotech focused on in‑vivo prime editing therapies.

  • FDA

    Cleared IND for PM647 and granted rare disease designations.

Every PRME earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$PRMEHighAI 8/10

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine (Nasdaq: PRME) closed a public offering of 41.07 million shares at $3.50 per share, raising $143.7 million. The offering included additional shares due to underwriters' full option exercise. Jefferies, TD Cowen, and Goldman Sachs led the offering. Proceeds will support the biotech company's gene editing therapies.

$PRMEMedAI 8/10

Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine reported Q3 2026 results, including dosing the first patient in a Phase 1/2 trial for PM577a in Wilson disease and FDA clearance for PM647 in Alpha-1 Antitrypsin Deficiency. The company plans a BLA submission for PM359 in early 2027 and raised $143.7 million in a public offering, with a cash runway through 2027. According to the CEO, these developments highlight the versatility of their platform and potential for expansion.

$PRMEMedAI 8/10

Prime Medicine Prices $125 Million Stock Offering at $3.50 Per Share

Prime Medicine (PRME) plans to raise $125 million via a public offering of 35.7 million shares at $3.50 each, with an option for $134.7 million if additional shares are purchased. Proceeds will fund disease programs and R&D. The offering is underwritten by Jefferies, TD Securities, and Goldman Sachs, and is expected to close around Nov 12, 2026, according to the company.